BI broadens research pact with Vanderbilt University to develop GPCR drugs for brain disorders

Boehringer Ingelheim has been working to boost its research capabilities in central nervous system (CNS) disorders, making moves over the past year aimed specifically at adding compounds to its pipeline to address Alzheimer’s disease (AD), schizophrenia and depression. Now it’s teaming up with Vanderbilt University, located in Nashville to develop novel small molecules that modulate

Continue Reading

FDA approve Alimta & Keytruda for combination lung cancer treatment

The US regulators have approved a combination of Eli Lilly’s Alimta and MSD’s Keytruda as first-line treatment for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status. The combination was approved via the FDA’s accelerated approval pathway based on Phase II tumour response rate and progression-free survival (PFS) data observed

Continue Reading